ZYBERNO
Stock Report
Updated Aug 31, 2026

ALDEYRA THERAPEUTICS, INC. (ALDX)

Healthcare • NASDAQ

$1.51

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
14.0/100
POOR BUSINESS
ALDEYRA THERAPEUTICS, INC. (ALDX) scores 14/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-53.1%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.01x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (0.0%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

ALDEYRA THERAPEUTICS, INC. (ALDX) stock report — Zyberno Score 14/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:1.51
Market Cap:$91.08M

Valuation Multiples (2)

P/B Ratio:2.40x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$21.33M

Price Action & Momentum (1)

% of 52-Week High:24.5%
B. Profitability Assessment

Return Metrics (3)

ROA:-34.9%
Reinvestment Rate:1.1%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$26.39
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:8.3%
Latest Earnings Filed:2026-08-06
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:4.91x
Quick Ratio:4.91x
Cash Ratio:7.25x

Leverage Analysis (3)

Debt To Equity Ttm:0.01x
Debt-to-Equity Ratio:0.01x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-24.84x
Times Interest Earned:-24.84

Capital Structure (4)

Working Capital:37,723,650.00
Cash And Cash Equivalents:70,041,254.00
Long Term Debt:$143.45K
Net Debt:-$69.75M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$24.07M

Bottom Line Performance (3)

-$23.05M
Income Before Tax:$33.85M
Ebitda Ttm:-23,808,760.00

Operating Expenses (5)

Operating Expenses:0.00
R And D Expense:15,628,391.00
Sga Expense:8,438,049.00
Income Tax Expense:$830.71K
Interest Expense:1,419,864.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$47.54M
Current Assets:$47.38M
Ppe Net:20,544.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:9,655,256.00
Current Liabilities:9,655,256.00
Long Term Debt:$143.45K
Short Term Debt:$143.45K

Equity & Capital (3)

Equity:$37.89M
Retained Earnings:-$492.86M
Common Stock:150,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:3,374,333.00

Special Items (2)

Contract Liabilities:6,000,000.00
Stock Based Compensation:1,643,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$25.99M$0.00

Investment Activities (1)

Investing Cash Flow:$0.00

Financing Activities (3)

Financing Cash Flow:$71.14K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:257,680.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-0.38
-$0.38
Earnings Per Share Ttm:-$0.38

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$0.55

Book Value & Capital (2)

Book Value Per Share:$0.63
Cash Per Share:1.16

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (1)

Reinvestment Rate:1.1%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):-32.4%
C. Company Profile & Context

Corporate Information (6)

Symbol:ALDX
Company Name:ALDEYRA THERAPEUTICS, INC.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:60.32M
Shares Outstanding Basic:60.32M
Shares Outstanding Diluted:60.32M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-31 17:21:31 UTC
Data Timestamp:2026-08-19T15:39:48.753162
Scroll to Top